{"name":"AmMax Bio, Inc.","slug":"ammax-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AMB-05X","genericName":"AMB-05X","slug":"amb-05x","indication":"Relapsing multiple sclerosis","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AMG820 and pembrolizumab","genericName":"AMG820 and pembrolizumab","slug":"amg820-and-pembrolizumab","indication":"Non-small cell lung cancer","status":"phase_1"}]}],"pipeline":[{"name":"AMB-05X","genericName":"AMB-05X","slug":"amb-05x","phase":"phase_2","mechanism":"AMB-05X is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"AMG820 and pembrolizumab","genericName":"AMG820 and pembrolizumab","slug":"amg820-and-pembrolizumab","phase":"phase_1","mechanism":"AMG820 is a monoclonal antibody targeting CD28 and pembrolizumab is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPQjZpT01CZ3ptUjEtNl82bTFXUVBkMlZLaXFZSW56QTg3c3lpbUhwY2NuOHI1dHd0WHgxNlo2X0wwbXJUSUszbXFnTjBnVzhpY3pqVHRPdTlRZDQ2NWl5Y1RvY1RWcE0wT0thWWVkdEZBQ195aEZ0V2psQnluZHJQLVA4YlluSUhlcXVIcExRNHU4UTZPQWZyR1RCcw?oc=5","date":"2025-05-30","type":"pipeline","source":"BioWorld News","summary":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B - BioWorld News","headline":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOSERqOXo3RmVqLWUzVzZROGdjeDdMWUJFRDFndFFuUEVKZVB1ZUFyN0trS3Q2ZkJZVC1BamQtdTBHYzlacGRqVTZIMC1tX04zc1NXV21URmlNSHlPMjMwYkozMHdacFVsNnljVURabG43YWo0bGdOSUlaNmVpZGVYWk5zZzREUDVSNFNaVVBodnQtSEdBLWRBRUNUM2ZzUldVUl85cGw2S0daYk9oLUFUQXFqdWJmdGh0d1JkTzh3anZORm5wMk5oZU55ZE5PN2FWYnBiQThGUW9waE10amtuSXMyQkYzaTdvckl3dHVQUERITlJzVmxKMnpNSDB4M1lpZ212cWQ1T3JVR2l6YVo1U3lLS3I?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZVVtME1seFN3SWd1Ri10T1lfdmFZdWU2dVp1bmRvcmFGczBneHV2bWxfd3h1UG85aGNlSUNSQlh1VXpidnNKSURSSDJlVVFGWmc4d0wyaTlCaTI2UnlvN283b0JoWDhJZzE2Q1J2N01mZ3ZUMm9BUGVzdmdZS3FJeHYwZDAzaS0wOHpqdURIU050Q0FubHoxR1BJS1AwQmhvN0FnUjlXcy05eGM?oc=5","date":"2025-02-18","type":"regulatory","source":"PharmTech.com","summary":"FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment - PharmTech.com","headline":"FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNLVlUMkZHbEdLRWZ4UUJnbXcxcV9kQXJETWg3UGMwMU1pU19wS25wSHZRVEdkcEpTY2F3UUtaM1BSbjFXZjJ1elN0a1BlWjUzYzlIN1lRSzE4QnlkdElNVXd5VUN1bEFHN1M3cUF3dGk1VEpYQ3BBanV1X1hLV1NpQXRmb1k0emZGVkRCQnF2c2pIdE5yeGpEbUpCZnFCZDhReWFYMng3NGNJOWdiTXVyQ0h6LXVrRHZnT2c?oc=5","date":"2022-05-31","type":"pipeline","source":"Business Wire","summary":"DTx Pharma Appoints Michael Huang, MD as Chief Medical Officer - Business Wire","headline":"DTx Pharma Appoints Michael Huang, MD as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQeVF4TWtZazZ3REUySy1pcGQxT0JQSEFQOVBNZXVKdjZJcW5UWTdacFNBMGxza3hKMFo1WlVKZ04ybGY0LTZEOVktU25sd05ReTl4UVNZdDN1NUhZazl1dWRMSlVtZ2l4TDFVdkF1STBuT25iNUZlV1Bsbnk4UXBsX0s4SU4tLXdaWTIyZkVSaUdMTEJWanFOT0dYMFEwVmtpNlJTeXp0a0FsQkpKWDFYYQ?oc=5","date":"2021-12-15","type":"patent","source":"The Business Journals","summary":"Larry Hsu 2.0: Generic drug trailblazer's new branded drug company targets rare tumors and more - The Business Journals","headline":"Larry Hsu 2.0: Generic drug trailblazer's new branded drug company targets rare tumors and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOdlFvWlBJdWpid3IyY0Jwb1FVLXBKXzFPN0VsNks1MGFzNkxtejVQMjB3cWR5WGJ5Rk1mQWhydGEweHZfR1cyUm5BMmtzUGFxeGZ3TDByWnB0Q1ZUXzBxSWhvMlFoZVVQcTlrOUloOGtOeFRTMzdXcl9uOVdlaHZXeGFMMA?oc=5","date":"2021-03-02","type":"pipeline","source":"citybiz","summary":"AmMax Bio Appoints John Varian to Board - citybiz","headline":"AmMax Bio Appoints John Varian to Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNbDlITGFtSkVkRzRxVTlDTVNsdEZWcE9ad3RxcnhMYkVNRkZwTDJ3TWNOY21xZE5vcm1QcUo2SXZBLV9pZG0xWkJFVWdsZEsxZmZtc0FhT29ocko5TDIxcnctM0xRZ3JxeWgtLWI1a1hxWjhiLVRKeWtCV3Y0UlZxRFQ1NUc5TmdFM2hkSXFLeFFJVTdrTzlBdlRYc2xyajNPU2pCM3RKZURYbFZfT2w2bVlkQ3Z5OTlnbmVuYUZaRXhiMXFSZ3d0TzFUZDI2S1JjSzJ2Tkk0TVVjb0ZrWGJHYVBPNEd0ekxEQUozaTdqWFJ5cXJ5ZmQ1X0JvVEsxQQ?oc=5","date":"2020-03-30","type":"regulatory","source":"Business Wire","summary":"LifeMax Launches AmMax Bio Following The License Of Worldwide Rights to a Clinical Stage Orphan Asset From Amgen - Business Wire","headline":"LifeMax Launches AmMax Bio Following The License Of Worldwide Rights to a Clinical Stage Orphan Asset From Amgen","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}